title: Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.
abstract: The fibrin-specific thrombolyticum tissue-type plasminogen activator (t-PA) has proven to be a potent drug in several clinical trials, but its clinical application is complicated by the rapid clearance of t-PA from the circulation. The rapid plasma clearance of t-PA results from the uptake of t-PA in the liver. t-PA consists of several domains which may be involved in the interaction with the liver. Three domain-deletion mutants, which were produced by the use of a cassette gene system, were studied in vivo and in vitro for their capacity to bind to the various types of rat liver cells. The three mutants lacked, in comparison to control t-PA, the epidermal growth factor (G) domain, the finger (F) domain or the G domain plus the first kringle (K1). The plasma clearance of the three mutants was slower than that of control t-PA. The slower plasma clearance resulted from a decreased liver uptake: 50 and 80% for t-PA mutants and control t-PA respectively. It was found that the K1 domain was of major importance for the uptake of t-PA by liver endothelial cells in vivo and in vitro. The high-affinity binding of t-PA (and t-PA mutants) to parenchymal liver cells depended largely on the presence of the G domain. Other domain(s), like the F, K2 or protease domain, may be responsible for low-affinity, t-PA-specific binding to rat parenchymal liver cells.
authors.affiliation: Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius laboratory, The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Kuiper
authors.forename: A
authors.initials: A
authors.lastname: Van't Hof
authors.forename: M
authors.initials: M
authors.lastname: Otter
authors.forename: E A
authors.initials: EA
authors.lastname: Biessen
authors.forename: D C
authors.initials: DC
authors.lastname: Rijken
authors.forename: T J
authors.initials: TJ
authors.lastname: van Berkel
mesh_terms: D000818:Animals; D001665:Binding Sites / Q000235:genetics; D001693:Biological Transport, Active; D004727:Endothelium / Q000166:cytology / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000378:metabolism; D006207:Half-Life; D066298:In Vitro Techniques; D018082:Kringles / Q000235:genetics; D008099:Liver / Q000166:cytology / Q000378:metabolism*; D008297:Male; D015394:Molecular Structure; D009154:Mutation; D051381:Rats; D017208:Rats, Wistar; D010959:Tissue Plasminogen Activator / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*
chemical_list: D004815:Epidermal Growth Factor; D010959:Tissue Plasminogen Activator